UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/14.01.26 | Market Closed - BOERSE MUENCHEN 20:40:38 17/05/2024 BST | ||
| 4.31 EUR | +6.16% |
|
| Current month | +67.70% | ||
| 1 month | +45.12% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 4.31 | +6.16% |
| 16/05/24 | 4.06 | +2.27% |
| 15/05/24 | 3.97 | +10.89% |
| 14/05/24 | 3.58 | -3.76% |
| 13/05/24 | 3.72 | +9.73% |
Real-time BOERSE MUENCHEN
Last update May 17, 2024 at 08:40 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD2FED |
| ISIN | DE000HD2FED8 |
| Date issued | 05/02/2024 |
| Strike | 550 $ |
| Maturity | 14/01/2026 (607 Days) |
| Parity | 10 : 1 |
| Emission price | 4.48 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.28 € |
|---|---|
| Lowest since issue | 2.54 € |
| Spread | 0.03 € |
| Spread % | 0.69% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Warrants
- Warrant
